申请人:The Upjohn Company
公开号:US03991070A1
公开(公告)日:1976-11-09
Preparing 1-halo-6-phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepines by reacting an N-halosuccinimide with a 2-[3-(phthalimidomethyl)triazolyl]benzophenone to form the 2-[5-halo-3-(phthalimidomethyl)triazolyl] benzophenone and reacting the 2-[5-halo-3-(phthalimidomethyl)triazol-4-yl]benzophenone with hydrazine or a primary amine in an organic liquid solvent medium at 25.degree. to 100.degree. C. The products of the process have CNS tranquilizer and sedative properties but are also of interest for use as intermediates to prepare 2,4-dihydro-6-phenyl-1H-s-triazolo[4,3-a] [1,4]benzodiazepin-1-ones which are of clinical interest for their CNS tranquilizer, sedative and anti-depressant drug use properties in mammalian animals including humans.
通过将N-卤代琥珀酰亚胺与2-[3-(邻苯二甲酰亚胺基)三唑基]苯基甲酮反应,制备1-卤代-6-苯基-4H-s-三唑并[4,3-a][1,4]苯二氮平。该反应生成2-[5-卤代-3-(邻苯二甲酰亚胺基)三唑基]苯基甲酮,再将其与肼或一级胺在有机液体溶剂介质中于25℃至100℃反应,得到本方法的产物具有中枢神经系统镇静和催眠作用,但也具有作为中间体制备2,4-二氢-6-苯基-1H-s-三唑并[4,3-a][1,4]苯二氮平的兴趣,该化合物在哺乳动物动物包括人类中具有中枢神经系统镇静剂、催眠剂和抗抑郁药物使用性质。